Exicure Inc (XCUR)

Form 8-K - Current report

Exicure Announces Board and Committee Changes

WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company...

Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement

WILMINGTON, Del., June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the “Company”) today...

Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) --  Exicure, Inc. (Nasdaq: XCUR, the “Company”) announced...

Form 8-K - Current report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB

Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100)

CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered...

Form 8-K - Current report

Form 8-K - Current report

Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage...

Form 8-K - Current report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]

Form 8-K - Current report

Exicure, Inc. Reports Full Year 2025 Financial Results

REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases...